US4166452A
(en)
|
1976-05-03 |
1979-09-04 |
Generales Constantine D J Jr |
Apparatus for testing human responses to stimuli
|
US4256108A
(en)
|
1977-04-07 |
1981-03-17 |
Alza Corporation |
Microporous-semipermeable laminated osmotic system
|
US4704362A
(en)
|
1977-11-08 |
1987-11-03 |
Genentech, Inc. |
Recombinant cloning vehicle microbial polypeptide expression
|
US4265874A
(en)
|
1980-04-25 |
1981-05-05 |
Alza Corporation |
Method of delivering drug with aid of effervescent activity generated in environment of use
|
DD296075A5
(de)
|
1989-08-07 |
1991-11-21 |
Martin-Luther-Universitaet Halle-Wittenberg,De |
Verfahren zur herstellung neuer inhibitoren der dipeptidyl peptidase iv
|
WO1991016339A1
(en)
|
1990-04-14 |
1991-10-31 |
New England Medical Center Hospitals, Inc. |
Inhibitors of dipeptidyl-aminopeptidase type iv
|
US5462856A
(en)
|
1990-07-19 |
1995-10-31 |
Bunsen Rush Laboratories, Inc. |
Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins
|
CA2121369C
(en)
|
1991-10-22 |
2003-04-29 |
William W. Bachovchin |
Inhibitors of dipeptidyl-aminopeptidase type iv
|
MX9206628A
(es)
|
1991-11-22 |
1993-05-01 |
Boehringer Ingelheim Pharma |
Ester de prolinaboronato y metodo para su preparacion.
|
US6100042A
(en)
|
1993-03-31 |
2000-08-08 |
Cadus Pharmaceutical Corporation |
Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
|
IL111785A0
(en)
|
1993-12-03 |
1995-01-24 |
Ferring Bv |
Dp-iv inhibitors and pharmaceutical compositions containing them
|
US5543396A
(en)
|
1994-04-28 |
1996-08-06 |
Georgia Tech Research Corp. |
Proline phosphonate derivatives
|
DE19616486C5
(de)
|
1996-04-25 |
2016-06-30 |
Royalty Pharma Collection Trust |
Verfahren zur Senkung des Blutglukosespiegels in Säugern
|
US20020006899A1
(en)
|
1998-10-06 |
2002-01-17 |
Pospisilik Andrew J. |
Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
|
JPH1081666A
(ja)
|
1996-06-12 |
1998-03-31 |
Ishihara Sangyo Kaisha Ltd |
フタルイミド誘導体又はその塩、それらの製造方法及びそれらを含有する医薬組成物
|
JPH10182613A
(ja)
|
1996-10-25 |
1998-07-07 |
Tanabe Seiyaku Co Ltd |
テトラヒドロイソキノリン誘導体
|
WO1998018763A1
(fr)
|
1996-10-25 |
1998-05-07 |
Tanabe Seiyaku Co., Ltd. |
Derives de tetrahydroisoquinoline
|
TW492957B
(en)
|
1996-11-07 |
2002-07-01 |
Novartis Ag |
N-substituted 2-cyanopyrrolidnes
|
US6040145A
(en)
|
1997-05-07 |
2000-03-21 |
Tufts University |
Potentiation of the immune response
|
US6100234A
(en)
|
1997-05-07 |
2000-08-08 |
Tufts University |
Treatment of HIV
|
US6183974B1
(en)
|
1997-07-31 |
2001-02-06 |
The General Hospital Corporation |
Screening assays for G protein coupled receptor agonists and antagonists
|
TR200000815T2
(tr)
|
1997-09-29 |
2000-12-21 |
Point Therapeutics Inc. |
In vitro hematopoietik hücrelerin stimulasyonu.
|
IT1295423B1
(it)
|
1997-10-10 |
1999-05-12 |
Medivis S R L |
Uso della flunarizina nella terapia topica del glaucoma
|
WO1999025719A1
(fr)
|
1997-11-18 |
1999-05-27 |
Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai |
Substance physiologiquement active, la sulphostine, procede de fabrication et utilisation
|
WO1999038501A2
(en)
|
1998-02-02 |
1999-08-05 |
Trustees Of Tufts College |
Method of regulating glucose metabolism, and reagents related thereto
|
US5922576A
(en)
|
1998-02-27 |
1999-07-13 |
The John Hopkins University |
Simplified system for generating recombinant adenoviruses
|
CA2331122A1
(en)
|
1998-05-04 |
1999-11-11 |
Point Therapeutics, Inc. |
Hematopoietic stimulation
|
DE19823831A1
(de)
|
1998-05-28 |
1999-12-02 |
Probiodrug Ges Fuer Arzneim |
Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
|
ATE231512T1
(de)
|
1998-06-05 |
2003-02-15 |
Point Therapeutics Inc |
Cyclische boroprolinverbindungen
|
DE19828114A1
(de)
|
1998-06-24 |
2000-01-27 |
Probiodrug Ges Fuer Arzneim |
Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
|
DE19828113A1
(de)
|
1998-06-24 |
2000-01-05 |
Probiodrug Ges Fuer Arzneim |
Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
|
DE19834591A1
(de)
|
1998-07-31 |
2000-02-03 |
Probiodrug Ges Fuer Arzneim |
Verfahren zur Steigerung des Blutglukosespiegels in Säugern
|
KR20010079669A
(ko)
|
1998-08-21 |
2001-08-22 |
바바라 피. 월너 |
기질 활성의 조절
|
WO2000020592A1
(en)
*
|
1998-10-07 |
2000-04-13 |
Medical College Of Georgia Research Institute, Inc. |
Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
|
US6242422B1
(en)
|
1998-10-22 |
2001-06-05 |
Idun Pharmacueticals, Inc. |
(Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
|
CO5150173A1
(es)
|
1998-12-10 |
2002-04-29 |
Novartis Ag |
Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
|
JP2000181616A
(ja)
|
1998-12-15 |
2000-06-30 |
Ricoh Co Ltd |
位置情報入力装置
|
JP2000191616A
(ja)
|
1998-12-24 |
2000-07-11 |
Senju Pharmaceut Co Ltd |
新規ジペプチジルアルデヒド誘導体およびそれを含有する医薬
|
US20030125539A1
(en)
|
1999-02-22 |
2003-07-03 |
Synaptic Pharmaceutical Corporation |
DNA encoding SNORF25 receptor
|
US6221660B1
(en)
*
|
1999-02-22 |
2001-04-24 |
Synaptic Pharmaceutical Corporation |
DNA encoding SNORF25 receptor
|
GB9906715D0
(en)
|
1999-03-23 |
1999-05-19 |
Ferring Bv |
Compositions for promoting growth
|
GB9906714D0
(en)
|
1999-03-23 |
1999-05-19 |
Ferring Bv |
Compositions for improving fertility
|
JP4121215B2
(ja)
|
1999-05-17 |
2008-07-23 |
財団法人微生物化学研究会 |
スルフォスチン類縁体、並びにスルフォスチン及びその類縁体の製造方法
|
AU781897B2
(en)
|
1999-05-25 |
2005-06-23 |
Point Therapeutics, Inc. |
Anti-tumor comprising boroproline compounds
|
JP4028135B2
(ja)
|
1999-05-27 |
2007-12-26 |
本田技研工業株式会社 |
物体検出装置
|
US6617340B1
(en)
|
1999-07-29 |
2003-09-09 |
Novartis Ag |
N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
|
DE19940130A1
(de)
|
1999-08-24 |
2001-03-01 |
Probiodrug Ges Fuer Arzneim |
Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
|
US6653064B1
(en)
|
1999-09-23 |
2003-11-25 |
Boehringer Ingelheim International Gmbh |
Method for identifying compounds useful in the therapy of bone disorders
|
GB9923177D0
(en)
|
1999-09-30 |
1999-12-01 |
Pfizer Ltd |
Novel polypeptide
|
JP2003535034A
(ja)
|
1999-11-12 |
2003-11-25 |
ギルフォード ファーマシューティカルズ インコーポレイテッド |
ジペプチジルペプチダーゼiv阻害剤並びにジペプチジルペプチダーゼiv阻害剤の製造及び使用法
|
US6380398B2
(en)
|
2000-01-04 |
2002-04-30 |
Novo Nordisk A/S |
Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
|
DE60132723T2
(de)
|
2000-01-21 |
2009-01-29 |
Novartis Pharma Ag |
Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
|
JP2003520849A
(ja)
|
2000-01-24 |
2003-07-08 |
ノボ ノルディスク アクティーゼルスカブ |
酵素dpp−ivの阻害剤であるn−置換2−シアノピロールおよび−ピロリン
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
GB0010188D0
(en)
|
2000-04-26 |
2000-06-14 |
Ferring Bv |
Inhibitors of dipeptidyl peptidase IV
|
GB0010183D0
(en)
|
2000-04-26 |
2000-06-14 |
Ferring Bv |
Inhibitors of dipeptidyl peptidase IV
|
ATE348162T1
(de)
|
2000-05-18 |
2007-01-15 |
Bayer Healthcare Ag |
Regulation eines menschlichen dopamine-ähnlichen g-protein gekoppelten rezeptor.
|
US6432969B1
(en)
|
2000-06-13 |
2002-08-13 |
Novartis Ag |
N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
|
TW583185B
(en)
|
2000-06-13 |
2004-04-11 |
Novartis Ag |
N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
|
GB0014969D0
(en)
|
2000-06-19 |
2000-08-09 |
Smithkline Beecham Plc |
Novel method of treatment
|
AU6895801A
(en)
|
2000-07-04 |
2002-01-14 |
Novo Nordisk As |
Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
|
AU7705601A
(en)
*
|
2000-07-25 |
2002-02-05 |
Merck & Co Inc |
N-substituted indoles useful in the treatment of diabetes
|
WO2002014271A1
(fr)
|
2000-08-10 |
2002-02-21 |
Mitsubishi Pharma Corporation |
Dérivés de proline et leur utilisation comme médicaments
|
JP4329290B2
(ja)
|
2000-10-06 |
2009-09-09 |
田辺三菱製薬株式会社 |
脂肪族含窒素五員環化合物
|
JP4329291B2
(ja)
|
2000-10-06 |
2009-09-09 |
田辺三菱製薬株式会社 |
含窒素五員環化合物
|
JP2004035574A
(ja)
|
2000-10-06 |
2004-02-05 |
Tanabe Seiyaku Co Ltd |
脂肪族含窒素五員環化合物
|
TWI290919B
(en)
|
2000-10-06 |
2007-12-11 |
Tanabe Seiyaku Co |
Nitrogen-containing five-membered ring compound, a pharmacologically permissible salt thereof and the method for producing the same
|
AUPR107800A0
(en)
|
2000-10-27 |
2000-11-23 |
University Of Sydney, The |
Peptide and nucleic acid molecule ii
|
TWI243162B
(en)
|
2000-11-10 |
2005-11-11 |
Taisho Pharmaceutical Co Ltd |
Cyanopyrrolidine derivatives
|
ES2280435T3
(es)
|
2000-12-01 |
2007-09-16 |
Astellas Pharma Inc. |
Metodo de exploracion de remedios para la diabetes.
|
US20040180925A1
(en)
|
2000-12-27 |
2004-09-16 |
Kenji Matsuno |
Dipeptidylpeptidase-IV inhibitor
|
US20040038942A1
(en)
|
2001-01-16 |
2004-02-26 |
Takumi Yamashita |
Medicament for treatment of bone marrow suppression, for treatment of infectious diseases and for increasing the number of leukocytes
|
JP4213390B2
(ja)
|
2001-02-02 |
2009-01-21 |
武田薬品工業株式会社 |
縮合複素環化合物
|
BR0206831A
(pt)
|
2001-02-02 |
2004-07-06 |
Takeda Chemical Industries Ltd |
Composto, cristal, agente farmacêutico, agentes para profilaxia ou tratamento de diabetes, de complicações diabéticas, de tolerância prejudicada à glucose e de obesidade, inibidor de peptidase, uso de um composto, e, método de produção de um composto
|
DK1953162T3
(da)
|
2001-02-24 |
2012-09-10 |
Boehringer Ingelheim Pharma |
Xanthinderivater, deres fremstilling og deres anvendelse som lægemiddel.
|
JP2002265439A
(ja)
|
2001-03-08 |
2002-09-18 |
Mitsubishi Pharma Corp |
シアノピロリジン誘導体およびその医薬用途
|
ATE395912T1
(de)
|
2001-03-27 |
2008-06-15 |
Merck & Co Inc |
Dipeptidylpeptidase-hemmer für die behandlung oder prävention von diabetes
|
WO2002080860A2
(en)
*
|
2001-03-27 |
2002-10-17 |
The Regents Of The University Of California |
Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
|
FR2822826B1
(fr)
|
2001-03-28 |
2003-05-09 |
Servier Lab |
Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
GB0109146D0
(en)
|
2001-04-11 |
2001-05-30 |
Ferring Bv |
Treatment of type 2 diabetes
|
US6573287B2
(en)
|
2001-04-12 |
2003-06-03 |
Bristo-Myers Squibb Company |
2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
|
FR2824825B1
(fr)
|
2001-05-15 |
2005-05-06 |
Servier Lab |
Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
JP2005500308A
(ja)
|
2001-06-20 |
2005-01-06 |
メルク エンド カムパニー インコーポレーテッド |
糖尿病を治療するためのジペプチジルペプチダーゼ阻害剤
|
AU2002344820B2
(en)
|
2001-06-20 |
2006-12-14 |
Merck & Co., Inc. |
Dipeptidyl peptidase inhibitors for the treatment of diabetes
|
GB0115517D0
(en)
|
2001-06-25 |
2001-08-15 |
Ferring Bv |
Novel antidiabetic agents
|
ATE455759T1
(de)
|
2001-06-27 |
2010-02-15 |
Smithkline Beecham Corp |
Fluoropyrrolidine als dipeptidylpeptidasehemmer
|
US20030130199A1
(en)
|
2001-06-27 |
2003-07-10 |
Von Hoersten Stephan |
Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
|
DE10154689A1
(de)
|
2001-11-09 |
2003-05-22 |
Probiodrug Ag |
Substituierte Aminoketonverbindungen
|
CN1471538A
(zh)
|
2001-06-27 |
2004-01-28 |
前体生物药物股份有限公司 |
用于竞争性调节二肽基肽酶iv催化的肽结构
|
US7368421B2
(en)
|
2001-06-27 |
2008-05-06 |
Probiodrug Ag |
Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
|
ES2296962T3
(es)
|
2001-06-27 |
2008-05-01 |
Smithkline Beecham Corporation |
Pirrolidinas como inhibidores de dipeptidil peptidasa.
|
JP2004521149A
(ja)
|
2001-06-27 |
2004-07-15 |
プロバイオドラッグ アーゲー |
新規なジペプチジルぺプチダ−ゼiv阻害剤およびそれらの抗癌剤としての使用
|
EP1399433B1
(de)
|
2001-06-27 |
2007-08-22 |
Smithkline Beecham Corporation |
Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
|
US6869947B2
(en)
|
2001-07-03 |
2005-03-22 |
Novo Nordisk A/S |
Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
|
JP2005502624A
(ja)
|
2001-07-03 |
2005-01-27 |
ノボ ノルディスク アクティーゼルスカブ |
糖尿病を治療するための、dpp−ivを阻害するプリン誘導体
|
UA74912C2
(en)
|
2001-07-06 |
2006-02-15 |
Merck & Co Inc |
Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
|
US6844316B2
(en)
|
2001-09-06 |
2005-01-18 |
Probiodrug Ag |
Inhibitors of dipeptidyl peptidase I
|
DE10143840A1
(de)
|
2001-09-06 |
2003-03-27 |
Probiodrug Ag |
Neue Inhibitoren der Dipeptidylpeptidase I
|
JPWO2003026661A1
(ja)
|
2001-09-14 |
2005-01-06 |
山之内製薬株式会社 |
インスリン分泌促進剤及び新規なピリミジン誘導体
|
CN100341862C
(zh)
|
2001-09-14 |
2007-10-10 |
三菱制药株式会社 |
噻唑烷衍生物及其医药用途
|
JP2005509603A
(ja)
|
2001-09-19 |
2005-04-14 |
ノボ ノルディスク アクティーゼルスカブ |
Dpp−iv酵素の阻害剤であるヘテロ環化合物
|
US7238671B2
(en)
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
JP2005514337A
(ja)
|
2001-10-18 |
2005-05-19 |
ブリストル−マイヤーズ スクイブ カンパニー |
ヒトグルカゴン様ペプチド−1模倣体、並びに糖尿病および関連疾患の処置におけるその使用
|
GB0125445D0
(en)
|
2001-10-23 |
2001-12-12 |
Ferring Bv |
Protease Inhibitors
|
GB0125446D0
(en)
|
2001-10-23 |
2001-12-12 |
Ferring Bv |
Novel anti-diabetic agents
|
US6861440B2
(en)
|
2001-10-26 |
2005-03-01 |
Hoffmann-La Roche Inc. |
DPP IV inhibitors
|
CA2464995A1
(en)
|
2001-10-31 |
2003-05-08 |
Novartis Ag |
Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
|
US20030125304A1
(en)
|
2001-11-09 |
2003-07-03 |
Hans-Ulrich Demuth |
Substituted amino ketone compounds
|
CA2466870A1
(en)
|
2001-11-26 |
2003-06-05 |
Trustees Of Tufts College |
Methods for treating autoimmune disorders, and reagents related thereto
|
WO2003045977A2
(en)
|
2001-11-26 |
2003-06-05 |
Trustees Of Tufts College |
Peptidomimetic Inhibitors of Post-Proline Cleaving Enzymes
|
WO2003057144A2
(en)
|
2001-12-26 |
2003-07-17 |
Guilford Pharmaceuticals |
Change inhibitors of dipeptidyl peptidase iv
|
US6727261B2
(en)
|
2001-12-27 |
2004-04-27 |
Hoffman-La Roche Inc. |
Pyrido[2,1-A]Isoquinoline derivatives
|
WO2003072528A2
(en)
|
2002-02-08 |
2003-09-04 |
Idun Pharmaceuticals, Inc. |
(substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
|
ES2345096T3
(es)
|
2002-02-13 |
2010-09-15 |
F. Hoffmann-La Roche Ag |
Nuevos derivados de piridina y pirimidina.
|
CN1308311C
(zh)
|
2002-02-13 |
2007-04-04 |
霍夫曼-拉罗奇有限公司 |
新型吡啶-和喹啉-衍生物
|
US6906074B2
(en)
|
2002-02-22 |
2005-06-14 |
Nippon Zoki Pharmaceutical Co., Ltd. |
2-phenylpiperazine derivatives
|
DE60304911D1
(de)
|
2002-02-25 |
2006-06-08 |
Eisai Co Ltd |
Xanthin-Derivate als DPP-IV-Inhibitoren
|
JP2004043429A
(ja)
|
2002-02-25 |
2004-02-12 |
Eisai Co Ltd |
新規キサンチン誘導体およびdppiv阻害剤
|
EA007434B1
(ru)
|
2002-02-28 |
2006-10-27 |
Прозидион Лимитед |
Ингибиторы dpiv на основе глутаминила
|
HUP0200849A2
(hu)
|
2002-03-06 |
2004-08-30 |
Sanofi-Synthelabo |
N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
|
EP1490335B1
(de)
|
2002-03-25 |
2007-09-19 |
Merck & Co., Inc. |
Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes
|
WO2003080633A1
(en)
|
2002-03-25 |
2003-10-02 |
Nippon Kayaku Kabushiki Kaisha |
Novel $g(a)-amino-n-(diaminophosphinyl)lactam derivative
|
JP4329381B2
(ja)
|
2002-04-04 |
2009-09-09 |
田辺三菱製薬株式会社 |
医薬組成物
|
JP4329382B2
(ja)
|
2002-04-04 |
2009-09-09 |
田辺三菱製薬株式会社 |
医薬組成物
|
JP2005532283A
(ja)
|
2002-04-08 |
2005-10-27 |
トレント・ファーマシューティカルズ・リミテッド |
チアゾリジン−4−カルボニトリル及び類似物ならびにジペプチジル−ペプチダーゼ阻害剤としてのそれらの使用
|
JP2003300977A
(ja)
|
2002-04-10 |
2003-10-21 |
Sumitomo Pharmaceut Co Ltd |
キサンチン誘導体
|
WO2003095425A1
(fr)
|
2002-05-09 |
2003-11-20 |
Taisho Pharmaceutical Co.,Ltd. |
Derives de cyanopyrrolidine
|
JP2004026820A
(ja)
|
2002-05-09 |
2004-01-29 |
Taisho Pharmaceut Co Ltd |
ジペプチジルペプチダーゼiv阻害剤
|
JP2003327532A
(ja)
|
2002-05-10 |
2003-11-19 |
Takeda Chem Ind Ltd |
ペプチダーゼ阻害剤
|
GB0212412D0
(en)
|
2002-05-29 |
2002-07-10 |
Novartis Ag |
Combination of organic compounds
|
JP3838941B2
(ja)
|
2002-05-31 |
2006-10-25 |
独立行政法人理化学研究所 |
コレステロール検出試薬
|
CN100402026C
(zh)
|
2002-06-03 |
2008-07-16 |
诺瓦提斯公司 |
取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途
|
US6710040B1
(en)
|
2002-06-04 |
2004-03-23 |
Pfizer Inc. |
Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
|
WO2003101449A2
(en)
|
2002-06-04 |
2003-12-11 |
Pfizer Products Inc. |
Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
|
EP1513808A2
(de)
|
2002-06-04 |
2005-03-16 |
Pfizer Products Inc. |
Fluorierte zyklische amide als dipeptidylpeptidase-iv inhibitoren
|
NZ536794A
(en)
|
2002-06-06 |
2007-04-27 |
Eisai Co Ltd |
Condensed imidazole derivatives
|
HUP0202001A2
(hu)
|
2002-06-14 |
2005-08-29 |
Sanofi-Aventis |
DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok
|
JP2004026678A
(ja)
|
2002-06-24 |
2004-01-29 |
Microbial Chem Res Found |
2型糖尿病治療剤
|
AU2003248921A1
(en)
|
2002-07-09 |
2004-01-23 |
Point Therapeutics, Inc. |
Boroproline compound combination therapy
|
JPWO2004007446A1
(ja)
|
2002-07-10 |
2005-11-10 |
アステラス製薬株式会社 |
新規なアゼチジン誘導体又はその塩
|
DE60330485D1
(de)
|
2002-07-15 |
2010-01-21 |
Merck & Co Inc |
Zur behandlung von diabetes
|
TW200401635A
(en)
|
2002-07-23 |
2004-02-01 |
Yamanouchi Pharma Co Ltd |
2-Cyano-4-fluoropyrrolidine derivative or salt thereof
|
JP4542757B2
(ja)
|
2002-08-08 |
2010-09-15 |
武田薬品工業株式会社 |
縮合複素環化合物
|
ATE401311T1
(de)
|
2002-08-08 |
2008-08-15 |
Takeda Pharmaceutical |
Kondensierte heterozyklische verbindungen als petidase inhibitoren
|
WO2004034968A2
(en)
*
|
2002-08-20 |
2004-04-29 |
The Regents Of The University Of California |
Combination therapy for controlling appetites
|
DE10238243A1
(de)
|
2002-08-21 |
2004-03-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
EP3424926A1
(de)
|
2002-08-21 |
2019-01-09 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
8-[3-amino-piperidin-1-yl]-xanthine, deren herstellung und deren verwendung als arzneimittel
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
DE10238477A1
(de)
|
2002-08-22 |
2004-03-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
DE10238470A1
(de)
|
2002-08-22 |
2004-03-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
BR0313831A
(pt)
|
2002-08-29 |
2005-07-05 |
Taisho Pharmaceutical Co Ltd |
Sais benzenossulfonato de derivados de 4-flúor-2-cianopirrolidina
|
US20060039974A1
(en)
|
2002-09-11 |
2006-02-23 |
Takeda Pharmaceutical Company Limited |
Sustained release preparation
|
WO2004024943A1
(ja)
|
2002-09-11 |
2004-03-25 |
Yamanouchi Pharmaceutical Co., Ltd. |
インスリン含量増加剤スクリーニング方法
|
AU2003275404A1
(en)
|
2002-10-07 |
2004-05-04 |
Merck & Co., Inc. |
Antidiabetic beta-amino heterocyclic dipeptidyl peptidase inhibitors
|
WO2004033455A2
(en)
|
2002-10-08 |
2004-04-22 |
Novo Nordisk A/S |
Hemisuccinate salts of heterocyclic dpp-iv inhibitors
|
DE60320008T2
(de)
|
2002-10-18 |
2009-06-18 |
Merck & Co., Inc. |
Heterozyklische beta-aminoverbindungen als inhibitoren des dipeptidylpeptidase zur behandlung bzw. prevention von diabetes
|
DE60332856D1
(de)
|
2002-10-23 |
2010-07-15 |
Bristol Myers Squibb Co |
Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
|
AU2003286776A1
(en)
|
2002-10-30 |
2004-06-07 |
Guilford Pharmaceuticals Inc. |
Novel inhibitors of dipeptidyl peptidase iv
|
AU2003280680A1
(en)
|
2002-11-01 |
2004-06-18 |
Sumitomo Pharmaceuticals Co., Ltd. |
Xanthine compound
|
MXPA05004890A
(es)
|
2002-11-07 |
2005-07-22 |
Merck & Co Inc |
Derivados de fenilalanina como inhibidores de dipeptidilpeptidasa para el tratamiento o prevencion de diabetes.
|
DE10251927A1
(de)
|
2002-11-08 |
2004-05-19 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
US7482337B2
(en)
|
2002-11-08 |
2009-01-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
|
JP2006508975A
(ja)
|
2002-11-18 |
2006-03-16 |
ファイザー・プロダクツ・インク |
ジペプチジルペプチダーゼivを阻害するフッ素化環状アミド
|
UY28103A1
(es)
|
2002-12-03 |
2004-06-30 |
Boehringer Ingelheim Pharma |
Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
|
DE10256264A1
(de)
|
2002-12-03 |
2004-06-24 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue substituierte Imidazo-pyridinone und Imidazo-pyridazinone, ihre Herstellung und ihre Verwendung als Arzneimittel
|
CA2508487A1
(en)
|
2002-12-04 |
2004-06-17 |
Merck & Co., Inc. |
Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
US7420079B2
(en)
|
2002-12-09 |
2008-09-02 |
Bristol-Myers Squibb Company |
Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
|
US20060111428A1
(en)
|
2002-12-10 |
2006-05-25 |
Pei-Ran Wang |
Combination of an dpp-iv inhibitor and a ppar-alpha compound
|
JP4504924B2
(ja)
|
2002-12-20 |
2010-07-14 |
メルク・シャープ・エンド・ドーム・コーポレイション |
糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての3−アミノ−4−フェニルブタン酸誘導体
|
RS20050532A
(en)
|
2003-01-14 |
2007-12-31 |
Arena Pharmaceuticals Inc., |
1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
|
US7265128B2
(en)
|
2003-01-17 |
2007-09-04 |
Merck & Co., Inc. |
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
JP2004244412A
(ja)
|
2003-01-20 |
2004-09-02 |
Kotobuki Seiyaku Kk |
4位に置換基を有する2−シアノピロリジン誘導体及びその製造方法並びにそれを含有する薬剤
|
AU2004207731B2
(en)
|
2003-01-31 |
2009-08-13 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
Compound inhibiting dipeptidyl peptidase iv
|
CA2513684A1
(en)
|
2003-01-31 |
2004-08-19 |
Merck & Co., Inc. |
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
WO2004071454A2
(en)
|
2003-02-13 |
2004-08-26 |
Guilford Pharmaceuticals Inc. |
Substituted azetidine compounds as inhibitors of dipeptidyl peptidase iv
|
PL378295A1
(pl)
|
2003-02-24 |
2006-03-20 |
Arena Pharmaceuticals, Inc. |
Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu glukozy oraz profilaktyka i leczenie zaburzeń tego metabolizmu
|
WO2004076433A1
(en)
|
2003-02-28 |
2004-09-10 |
Aic |
Dipeptidyl peptidase inhibitors
|
WO2004076434A1
(en)
|
2003-02-28 |
2004-09-10 |
Aic |
Dipeptidyl peptidase inhibitors
|
JP2004269469A
(ja)
|
2003-03-12 |
2004-09-30 |
Yamanouchi Pharmaceut Co Ltd |
ピリミジン誘導体又はその塩
|
JP2004269468A
(ja)
|
2003-03-12 |
2004-09-30 |
Yamanouchi Pharmaceut Co Ltd |
ピリミジン誘導体又はその塩
|
AR043515A1
(es)
|
2003-03-19 |
2005-08-03 |
Merck & Co Inc |
Procedimiento para preparar derivados quirales beta aminoacidos mediante hidrogenacion asimetrica
|
WO2004085661A2
(en)
|
2003-03-24 |
2004-10-07 |
Merck & Co., Inc |
Process to chiral beta-amino acid derivatives
|
US7687625B2
(en)
|
2003-03-25 |
2010-03-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
WO2004087650A2
(en)
|
2003-03-27 |
2004-10-14 |
Merck & Co. Inc. |
Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-iv inhibitors
|
WO2004092128A1
(en)
|
2003-04-10 |
2004-10-28 |
Smithkline Beecham Corporation |
Anhydrous crystalline forms of (2s, 4s)-1-{(2r)-2-amino-3-‘4-methoxybenzyl)sulfonyl!-3-methylbutanoyl}-4-fluoropyrrolindine-2-carbonitrile
|
WO2004096806A1
(ja)
|
2003-04-30 |
2004-11-11 |
Sumitomo Pharmaceuticals Co. Ltd. |
縮合イミダゾール誘導体
|
WO2004099134A2
(en)
|
2003-05-05 |
2004-11-18 |
Prosidion Ltd. |
Glutaminyl based dp iv-inhibitors
|
ATE462432T1
(de)
|
2003-05-05 |
2010-04-15 |
Probiodrug Ag |
Glutaminylcyclase-hemmer
|
US7083933B1
(en)
|
2003-05-09 |
2006-08-01 |
Prosidion Limited |
Methods for identification of modulators of OSGPR116 activity
|
WO2004103993A1
(en)
|
2003-05-14 |
2004-12-02 |
Syrrx, Inc. |
Dipeptidyl peptidase inhibitors
|
CA2524531A1
(en)
|
2003-05-14 |
2004-12-02 |
Merck And Co., Inc. |
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
US20060293297A1
(en)
|
2003-05-15 |
2006-12-28 |
Hiroshi Fukushima |
Cyanofluoropyrrolidine derviative
|
EP1631680A2
(de)
|
2003-05-21 |
2006-03-08 |
Bayer HealthCare AG |
Diagnostika und therapeutika für dipeptidylpeptidase iv (dpp4) assoziierte erkrangkungen
|
EP1631679A2
(de)
|
2003-05-21 |
2006-03-08 |
Bayer HealthCare AG |
Diagnostika und therapeutika, die mit der dipeptidylpeptidase 7 (dpp7) assoziiert sind
|
AU2003902828A0
(en)
|
2003-06-05 |
2003-06-26 |
Fujisawa Pharmaceutical Co., Ltd. |
Dpp-iv inhibitor
|
CA2526770A1
(en)
|
2003-06-06 |
2004-12-23 |
Merck & Co., Inc. |
Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
US20070099884A1
(en)
|
2003-06-06 |
2007-05-03 |
Erondu Ngozi E |
Combination therapy for the treatment of diabetes
|
AU2003902946A0
(en)
|
2003-06-12 |
2003-06-26 |
Fujisawa Pharmaceutical Co., Ltd. |
Dpp-iv inhibitor
|
US7456204B2
(en)
|
2003-06-17 |
2008-11-25 |
Merck & Co., Inc. |
Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
DE10327439A1
(de)
|
2003-06-18 |
2005-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
BRPI0411713B8
(pt)
|
2003-06-20 |
2021-05-25 |
Hoffmann La Roche |
compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e sua utilização
|
AU2004251829B2
(en)
|
2003-06-20 |
2009-12-17 |
F. Hoffmann-La Roche Ag |
Hexahydropyridoisoqinolines as DPP-IV inhibitors
|
JO2625B1
(en)
|
2003-06-24 |
2011-11-01 |
ميرك شارب اند دوم كوربوريشن |
Phosphoric acid salts of dipeptidyl betidase inhibitor 4
|
JP2005023038A
(ja)
|
2003-07-04 |
2005-01-27 |
Taisho Pharmaceut Co Ltd |
慢性腎疾患治療薬
|
AR045047A1
(es)
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
|
MXPA06000554A
(es)
|
2003-07-14 |
2006-07-03 |
Arena Pharm Inc |
Derivados arilo y heteroarilo fusionados como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con los mismos.
|
CA2532397A1
(en)
|
2003-07-21 |
2005-02-03 |
Smithkline Beecham Corporation |
(2s,4s)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-l-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof
|
US7094800B2
(en)
|
2003-07-25 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Cyanopyrrolidides, process for their preparation and their use as medicaments
|
PE20050249A1
(es)
|
2003-07-25 |
2005-06-01 |
Aventis Pharma Gmbh |
Nuevas cianopirrolididas y procedimiento para su preparacion como medicamentos
|
DE10333935A1
(de)
|
2003-07-25 |
2005-02-24 |
Aventis Pharma Deutschland Gmbh |
Neue bicyclische Cyanoheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
US7008957B2
(en)
|
2003-07-25 |
2006-03-07 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
|
EP1653909A4
(de)
|
2003-07-28 |
2009-04-08 |
Britesmile Professional Inc |
Zusammensetzungen, verfahren, vorrichtungen und kits zur aufrechterhaltung oder verbesserung der zahnaufhellung
|
ATE417832T1
(de)
|
2003-07-31 |
2009-01-15 |
Merck & Co Inc |
Hexahydrodiazepinone als inhibitoren des dipeptidylpeptidase-iv zur behandlung bzw. prävention von diabetes
|
US6995183B2
(en)
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
WO2005019168A2
(en)
|
2003-08-20 |
2005-03-03 |
Pfizer Products Inc. |
Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors
|
HU227684B1
(en)
|
2003-08-29 |
2011-11-28 |
Sanofi Aventis |
Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
|
EP1659123A1
(de)
|
2003-08-29 |
2006-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Bicyclisches pyrazolderivat
|
EP1662876A4
(de)
|
2003-09-02 |
2009-01-14 |
Merck & Co Inc |
Neue kristalline formen eines phosphorsäuresalzes eines dipeptidylpeptidase-iv-hemmers
|
WO2005023762A1
(en)
|
2003-09-04 |
2005-03-17 |
Abbott Laboratories |
Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
|
WO2005030751A2
(en)
|
2003-09-08 |
2005-04-07 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
JP2007505121A
(ja)
|
2003-09-08 |
2007-03-08 |
武田薬品工業株式会社 |
ジペプチジルぺプチダーゼ阻害剤
|
AR046330A1
(es)
|
2003-09-09 |
2005-12-07 |
Japan Tobacco Inc |
Inhibidor de dipeptidilpeptidasa iv
|
WO2005030127A2
(en)
|
2003-09-23 |
2005-04-07 |
Merck & Co., Inc. |
Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
|
EP1671649B1
(de)
|
2003-10-03 |
2011-11-23 |
Takeda Pharmaceutical Company Limited |
Dipeptidylpeptidase-IV-Inhibitoren zur Behandlung von Diabetes-Patienten mit Sekundärversagen durch Sulfonylharnstoffe
|
WO2005033099A2
(en)
|
2003-10-03 |
2005-04-14 |
Glenmark Pharmaceuticals Ltd. |
Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
|
DE10348022A1
(de)
|
2003-10-15 |
2005-05-25 |
Imtm Gmbh |
Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
|
DE10348044A1
(de)
|
2003-10-15 |
2005-05-19 |
Imtm Gmbh |
Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
|
GB0324236D0
(en)
|
2003-10-16 |
2003-11-19 |
Astrazeneca Ab |
Chemical compounds
|
TW200519105A
(en)
|
2003-10-20 |
2005-06-16 |
Lg Life Science Ltd |
Novel inhibitors of DPP-IV, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
|
TW200523252A
(en)
|
2003-10-31 |
2005-07-16 |
Takeda Pharmaceutical |
Pyridine compounds
|
TW200528440A
(en)
|
2003-10-31 |
2005-09-01 |
Fujisawa Pharmaceutical Co |
2-cyanopyrrolidinecarboxamide compound
|
WO2005044195A2
(en)
|
2003-11-04 |
2005-05-19 |
Merck & Co., Inc. |
Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
US7674913B2
(en)
|
2003-11-12 |
2010-03-09 |
Phenomix Corporation |
Heterocyclic boronic acid compounds
|
CA2545641A1
(en)
|
2003-11-17 |
2005-06-02 |
Novartis Ag |
Use of organic compounds
|
DE10355304A1
(de)
|
2003-11-27 |
2005-06-23 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
WO2005058849A1
(en)
|
2003-12-15 |
2005-06-30 |
Glenmark Pharmaceuticals Ltd. |
New dipeptidyl peptidase in inhibitors; process for their preparation and compositions containing them
|
US7217711B2
(en)
|
2003-12-17 |
2007-05-15 |
Boehringer Ingelheim International Gmbh |
Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions
|
DE10360835A1
(de)
|
2003-12-23 |
2005-07-21 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
|
NZ547965A
(en)
|
2003-12-24 |
2009-12-24 |
Prosidion Ltd |
1,2,4-Oxadiazole derivatives as GPCR receptor agonists
|
WO2005072530A1
(en)
|
2004-01-16 |
2005-08-11 |
Merck & Co., Inc. |
Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor
|
WO2005075426A1
(en)
|
2004-02-03 |
2005-08-18 |
Glenmark Pharmaceuticals Ltd. |
Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
RU2394570C2
(ru)
|
2004-02-20 |
2010-07-20 |
Новартис Аг |
Ингибиторы dpp-iv для лечения нейродегенерации и когнитивных расстройств
|
US20090209491A1
(en)
|
2004-02-23 |
2009-08-20 |
Trustees Of Tufts College |
Lactams as conformationally constrained peptidomimetic inhibitors
|
US20050203027A1
(en)
|
2004-02-23 |
2005-09-15 |
Trustees Of Tufts College |
Inhibitors of dipeptidylpeptidase IV
|
DE102004009039A1
(de)
|
2004-02-23 |
2005-09-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
|
AU2005221678B2
(en)
|
2004-03-09 |
2008-10-09 |
National Health Research Institutes |
Pyrrolidine compounds
|
CN102134229B
(zh)
|
2004-03-15 |
2020-08-04 |
武田药品工业株式会社 |
二肽基肽酶抑制剂
|
WO2005095339A1
(en)
|
2004-03-31 |
2005-10-13 |
Pfizer Products Inc. |
Dicyanopyrrolidines as dipeptidyl peptidase iv inhibitors
|
TW200538122A
(en)
|
2004-03-31 |
2005-12-01 |
Bristol Myers Squibb Co |
Process for preparing a dipeptidyl peptidase Ⅳ inhibitor and intermediates employed therein
|
US7741082B2
(en)
|
2004-04-14 |
2010-06-22 |
Bristol-Myers Squibb Company |
Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor
|
WO2005100334A1
(en)
|
2004-04-14 |
2005-10-27 |
Pfizer Products Inc. |
Dipeptidyl peptidase-iv inhibitors
|
US7687492B2
(en)
|
2004-05-04 |
2010-03-30 |
Merck Sharp & Dohme Corp. |
1,2,4-Oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
|
RS51106B
(sr)
|
2004-05-12 |
2010-10-31 |
Pfizer Products Inc. |
Derivati prolina i njihova upotreba kao inhibitora dipeptidil peptidaze iv
|
CN1960990A
(zh)
|
2004-05-18 |
2007-05-09 |
默克公司 |
作为用于治疗或预防糖尿病的二肽基肽酶-ⅳ抑制剂的环己基丙氨酸衍生物
|
JP2005336066A
(ja)
|
2004-05-25 |
2005-12-08 |
Mitsubishi Chemicals Corp |
(メタ)アクロレイン又は(メタ)アクリル酸の製造方法
|
US7214702B2
(en)
|
2004-05-25 |
2007-05-08 |
Bristol-Myers Squibb Company |
Process for producing a dipeptidyl peptidase IV inhibitor
|
WO2005118555A1
(en)
|
2004-06-04 |
2005-12-15 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
ATE415397T1
(de)
*
|
2004-06-04 |
2008-12-15 |
Arena Pharm Inc |
Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
|
EP1604989A1
(de)
|
2004-06-08 |
2005-12-14 |
Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft |
DPP-IV-Hemmer
|
EP1604980A1
(de)
|
2004-06-08 |
2005-12-14 |
Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft |
DPP-IV-Hemmer
|
EP1604662A1
(de)
|
2004-06-08 |
2005-12-14 |
Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft |
1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidin-(2R)-carbonsäure-benzylamine-Derivate und verwandte Verbindungen als Dipeptidyl-Peptidase IV (DPP-IV) Inhibitoren zur Behandlung von Typ 2 Diabetes Mellitus
|
GB0413389D0
(en)
|
2004-06-16 |
2004-07-21 |
Astrazeneca Ab |
Chemical compounds
|
CA2570807C
(en)
|
2004-06-21 |
2011-12-06 |
Merck & Co., Inc. |
Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
WO2006000577A2
(en)
*
|
2004-06-24 |
2006-01-05 |
Galapagos N.V. |
Lxr agonists to promote bone homeostasis
|
US20060024313A1
(en)
|
2004-07-06 |
2006-02-02 |
Xin Chen |
Agents that disrupt dimer formation in DPP-IV family of prolyl dipeptidases
|
WO2006019965A2
(en)
|
2004-07-16 |
2006-02-23 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
US7842707B2
(en)
|
2004-07-23 |
2010-11-30 |
Nuada, Llc |
Peptidase inhibitors
|
WO2006011035A1
(en)
|
2004-07-23 |
2006-02-02 |
Glenmark Pharmaceuticals Ltd. |
Novel dipeptidyl peptidase iv inhibitors; process for their preparation and compositions containing them
|
WO2006012441A1
(en)
|
2004-07-23 |
2006-02-02 |
Susan Marie Royalty |
Peptidase inhibitors
|
DE102004037554A1
(de)
|
2004-08-03 |
2006-03-16 |
Sanofi-Aventis Deutschland Gmbh |
Substituierte 8-Aminoalkylthio-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
EP1623983A1
(de)
|
2004-08-05 |
2006-02-08 |
Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft |
Heterozyklische Verbindungen verwendbar als DDP-IV-Inhibitoren
|
DE102004038268A1
(de)
|
2004-08-06 |
2006-03-16 |
Sanofi-Aventis Deutschland Gmbh |
Substituierte, bizyklische 8-Pyrrolidino-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
AU2005277283A1
(en)
|
2004-08-23 |
2006-03-02 |
Merck Sharp & Dohme Corp. |
Fused triazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
|
US20060046978A1
(en)
|
2004-08-31 |
2006-03-02 |
Morphochem Ag |
Novel compounds that inhibit dipeptidyl peptidase (DPP-IV) and neprilysin (NEP) and/or angiotensin converting enzyme (ACE)
|
DE102004043944A1
(de)
|
2004-09-11 |
2006-03-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
DE102004044221A1
(de)
|
2004-09-14 |
2006-03-16 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
US7612072B2
(en)
|
2004-09-15 |
2009-11-03 |
Merck & Co., Inc. |
Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
|
WO2006030847A1
(ja)
|
2004-09-17 |
2006-03-23 |
Dainippon Sumitomo Pharma Co., Ltd. |
新規二環性ピラゾール誘導体
|
ATE481969T1
(de)
|
2004-10-01 |
2010-10-15 |
Merck Sharp & Dohme |
Aminopiperidine als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes
|
CN101048368A
(zh)
*
|
2004-10-07 |
2007-10-03 |
默克公司 |
作为大麻素受体调节剂的非环状酰肼
|
CA2583259C
(en)
|
2004-10-08 |
2011-08-02 |
Astellas Pharma Inc. |
Aromatic ring fused pyrimidine derivative
|
EP1799639B1
(de)
|
2004-10-12 |
2013-09-04 |
Glenmark Pharmaceuticals S.A. |
Neue dipeptidylpeptidase-iv-inhibitoren, pharmazeutische zusammensetzungen, die diese enthalten, und verfahren zu deren herstellung
|
TW200621257A
(en)
|
2004-10-20 |
2006-07-01 |
Astellas Pharma Inc |
Pyrimidine derivative fused with nonaromatic ring
|
CA2587800C
(en)
|
2004-11-29 |
2012-06-12 |
Merck & Co., Inc. |
Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
BRPI0516667A
(pt)
|
2004-11-30 |
2008-09-16 |
Hoffmann La Roche |
compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e utilização desses compostos
|
US7411093B2
(en)
|
2004-12-20 |
2008-08-12 |
Hoffman-La Roche Inc. |
Aminocycloalkanes as DPP-IV inhibitors
|
EP1828192B1
(de)
|
2004-12-21 |
2014-12-03 |
Takeda Pharmaceutical Company Limited |
Dipeptidylpeptidasehemmer
|
US8193359B2
(en)
|
2004-12-24 |
2012-06-05 |
Prosidion Limited |
G-protein coupled receptor agonists
|
BRPI0518651A2
(pt)
|
2004-12-24 |
2008-12-02 |
Dainippon Sumitomo Pharma |
composto, uma prà-droga do mesmo, ou um sal do composto ou prà-droga farmaceuticamente aceitÁvel, composiÇço farmacÊutica, inibidor de dipeptidil peptidase iv, uso de um composto, uma prà-droga do mesmo ou um sal do composto ou prà-droga farmaceuticamente aceitÁvel, e, mÉtodo para tratar diabetes
|
CA2591922A1
(en)
|
2004-12-24 |
2006-06-29 |
Prosidion Limited |
G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
|
US7635699B2
(en)
|
2004-12-29 |
2009-12-22 |
Bristol-Myers Squibb Company |
Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7589088B2
(en)
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
GB0428514D0
(en)
|
2004-12-31 |
2005-02-09 |
Prosidion Ltd |
Compounds
|
DOP2006000008A
(es)
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
MY148521A
(en)
*
|
2005-01-10 |
2013-04-30 |
Arena Pharm Inc |
Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
|
US20070032420A1
(en)
|
2005-02-09 |
2007-02-08 |
Entelos, Inc. |
Treating diabetes with glucagon-like peptide-1 secretagogues
|
EP1902730A4
(de)
|
2005-06-09 |
2009-11-11 |
Banyu Pharma Co Ltd |
Npy-y2-agonist zur verwendung als heilmittel für durch diarrhoe begleitete erkrankungen
|
JP5114395B2
(ja)
|
2005-06-30 |
2013-01-09 |
プロシディオン・リミテッド |
Gpcrアゴニスト
|
BRPI0613505A2
(pt)
|
2005-06-30 |
2011-01-11 |
Prosidion Ltd |
agonistas de gpcr
|
AU2006264651A1
(en)
|
2005-06-30 |
2007-01-11 |
Prosidion Limited |
G-protein coupled receptor agonists
|
EP1907384A2
(de)
|
2005-06-30 |
2008-04-09 |
Prosidion Limited |
Gpcr-agonisten
|
US7708191B2
(en)
*
|
2005-07-28 |
2010-05-04 |
Edwin Vega |
Telebanking apparatus for transferring money or cash value between two parties in the same country or across national borders, for paying bills and browsing the internet
|
US7813092B2
(en)
|
2005-09-19 |
2010-10-12 |
The Regents Of The University Of California |
ESD unit protection cell for distributed amplifiers
|
EP1971862B1
(de)
*
|
2006-04-11 |
2010-11-10 |
Arena Pharmaceuticals, Inc. |
Verfahren zur verwendung des gpr119-rezeptors zur identifizierung von verbindungen zur erhöhung der knochenmasse bei einer person
|
PE20071221A1
(es)
*
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
EP2043744A2
(de)
*
|
2006-07-13 |
2009-04-08 |
SmithKline Beecham Corporation |
Chemische verbindungen
|
US20080103123A1
(en)
|
2006-08-30 |
2008-05-01 |
Biovitrum |
New compounds
|
EP2146210A1
(de)
|
2008-04-07 |
2010-01-20 |
Arena Pharmaceuticals, Inc. |
Verfahren zur Verwendung eines AG-Protein-gekoppelten Rezeptors zur Identifikation von Peptid-YY (PPY)-Sekretagogen sowie Verbindungen zur Behandlung durch PYY modulierter Leiden
|
EP2996378B1
(de)
|
2013-06-19 |
2019-01-30 |
Huawei Technologies Co., Ltd. |
Kommunikationsqualitätsmessverfahren
|